Fractionated cylophosphamide and back to back high dose methotrexate and cytosine arabinoside improves outcome in patients with stage III high grade small non-cleaved cell lymphomas (SNCCL): a randomized trial of the Pediatric Oncology Group - PubMed
- ️Mon Jul 03 2006
Clinical Trial
Fractionated cylophosphamide and back to back high dose methotrexate and cytosine arabinoside improves outcome in patients with stage III high grade small non-cleaved cell lymphomas (SNCCL): a randomized trial of the Pediatric Oncology Group
M L Brecher et al. Med Pediatr Oncol. 1997 Dec.
Abstract
Background: The Pediatric Oncology Group (POG) conducted a two-arm, randomized study for the treatment of children and adolescents with stage III small, non-cleaved cell lymphoma (SNCCL). Regimen A, based on the group's previous best treatment for this group of patients, included cyclophosphamide (CTX) and high-dose methotrexate (MTX), as well as vincristine (VCR), prednisone (PRED), and intrathecal (IT) chemoprophylaxis. Regimen B, based on a single institution pilot study (Total B therapy), consisted of two rapidly alternating chemotherapy combinations (CTX, VCR, doxorubicin; MTX, and cytarabine (Ara-C) plus coordinated IT chemotherapy.
Procedure: One hundred thirty-four consecutive patients were entered on this study. Seventy patients were randomized to Regimen A, and 64 patients to Regimen B. One hundred and twenty-two patients are eligible for response.
Results: Complete remission (CR) was achieved by 81% (52/64) of patients on Regimen A, and 95% (55/58) of patients on Regimen B (p=0.014 one-sided). The two-year event-free survival (EFS) is 64% (SE=6%) on Regimen A, and 79% (SE=6%) on Regimen B (p=0.027 by one-sided logrank test). No patient has relapsed on either regimen after a year from diagnosis, although one patient had a second malignancy at day 371. Severe, but manageable, hematologic toxicity was seen in the majority of patients on both regimens, but was more frequent on Regimen B.
Conclusions: We conclude that the cure rate in stage III SNCCL is significantly improved with the use of a short, six-month chemotherapy regimen of fractionated CTX alternated with coordinated MTX and Ara-C. Results suggest that drug schedule, not simple drug selection, influences outcome.
Similar articles
-
Bowman WP, Shuster JJ, Cook B, Griffin T, Behm F, Pullen J, Link M, Head D, Carroll A, Berard C, Murphy S. Bowman WP, et al. J Clin Oncol. 1996 Apr;14(4):1252-61. doi: 10.1200/JCO.1996.14.4.1252. J Clin Oncol. 1996. PMID: 8648381 Clinical Trial.
-
Sullivan MP, Brecher M, Ramirez I, Ragab A, Hvizdala E, Pullen J, Shuster J, Berard C, Crist W, Vietti T. Sullivan MP, et al. Am J Pediatr Hematol Oncol. 1991 Fall;13(3):288-95. doi: 10.1097/00043426-199123000-00007. Am J Pediatr Hematol Oncol. 1991. PMID: 1793154 Clinical Trial.
-
Disseminated nonlymphoblastic lymphoma of childhood: a Childrens Cancer Group study, CCG-552.
Finlay JL, Anderson JR, Cecalupo AJ, Hutchinson RJ, Kadin ME, Kjeldsberg CR, Provisor AJ, Woods WG, Meadows AT. Finlay JL, et al. Med Pediatr Oncol. 1994;23(6):453-63. doi: 10.1002/mpo.2950230602. Med Pediatr Oncol. 1994. PMID: 7935170 Clinical Trial.
-
Hagemeister FB. Hagemeister FB. Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. doi: 10.1007/s00280-002-0447-1. Epub 2002 Apr 12. Cancer Chemother Pharmacol. 2002. PMID: 12042984 Review.
-
Lee EJ, Petroni GR, Schiffer CA, Freter CE, Johnson JL, Barcos M, Frizzera G, Bloomfield CD, Peterson BA. Lee EJ, et al. J Clin Oncol. 2001 Oct 15;19(20):4014-22. doi: 10.1200/JCO.2001.19.20.4014. J Clin Oncol. 2001. PMID: 11600602 Review.
Cited by
-
Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, Sposto R, Weston C, Raphael M, Perkins SL, McCarthy K, Cairo MS; FAB/LMB96 International Study Committee. Patte C, et al. Blood. 2007 Apr 1;109(7):2773-80. doi: 10.1182/blood-2006-07-036673. Blood. 2007. PMID: 17132719 Free PMC article. Clinical Trial.
-
Outcomes for children and adolescents with cancer: challenges for the twenty-first century.
Smith MA, Seibel NL, Altekruse SF, Ries LA, Melbert DL, O'Leary M, Smith FO, Reaman GH. Smith MA, et al. J Clin Oncol. 2010 May 20;28(15):2625-34. doi: 10.1200/JCO.2009.27.0421. Epub 2010 Apr 19. J Clin Oncol. 2010. PMID: 20404250 Free PMC article.
-
Therapeutic interventions for Burkitt lymphoma in children.
Okebe JU, Skoetz N, Meremikwu MM, Richards S. Okebe JU, et al. Cochrane Database Syst Rev. 2011 Jul 6;2011(7):CD005198. doi: 10.1002/14651858.CD005198.pub3. Cochrane Database Syst Rev. 2011. PMID: 21735399 Free PMC article. Review.
-
Sandlund JT, Santana VM, Hudson MM, Onciu M, Head D, Murry DJ, Ribeiro R, Wallace D, Rencher R, Pui CH. Sandlund JT, et al. Cancer. 2008 Aug 15;113(4):782-90. doi: 10.1002/cncr.23630. Cancer. 2008. PMID: 18618501 Free PMC article. Clinical Trial.
-
Cairo MS, Sposto R, Gerrard M, Auperin A, Goldman SC, Harrison L, Pinkerton R, Raphael M, McCarthy K, Perkins SL, Patte C. Cairo MS, et al. J Clin Oncol. 2012 Feb 1;30(4):387-93. doi: 10.1200/JCO.2010.33.3369. Epub 2012 Jan 3. J Clin Oncol. 2012. PMID: 22215753 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources